Crestor 10 mg 挪威 - 挪威文 - Statens legemiddelverk

crestor 10 mg

grünenthal gmbh - rosuvastatinkalsium - tablett, filmdrasjert - 10 mg

Crestor 5 mg 挪威 - 挪威文 - Statens legemiddelverk

crestor 5 mg

grünenthal gmbh - rosuvastatinkalsium - tablett, filmdrasjert - 5 mg

Crestor 20 mg 挪威 - 挪威文 - Statens legemiddelverk

crestor 20 mg

grünenthal gmbh - rosuvastatinkalsium - tablett, filmdrasjert - 20 mg

Crestor 40 mg 挪威 - 挪威文 - Statens legemiddelverk

crestor 40 mg

grünenthal gmbh - rosuvastatinkalsium - tablett, filmdrasjert - 40 mg

Tenofovir disoproxil Teva 245 mg 挪威 - 挪威文 - Statens legemiddelverk

tenofovir disoproxil teva 245 mg

teva pharma b.v. (4) - tenofovirdisoproksilfumarat - tablett, filmdrasjert - 245 mg

Onpattro 欧盟 - 挪威文 - EMA (European Medicines Agency)

onpattro

alnylam netherlands b.v. - patisiran sodium - amyloidose, familiær - andre nervesystemet narkotika - onpattro er angitt for behandling av arvelig transthyretin-mediert amyloidose (hattr amyloidose) hos voksne pasienter med stadium 1 eller nivå 2 polynevropati.

Pifeltro 欧盟 - 挪威文 - EMA (European Medicines Agency)

pifeltro

merck sharp & dohme b.v. - doravirine - hiv-infeksjoner - antivirale midler til systemisk bruk - pifeltro is indicated, in combination with other antiretroviral medicinal products, for the treatment of adults, and adolescents aged 12 years and older weighing at least 35 kg infected with hiv 1 without past or present evidence of resistance to the nnrti class.

Cufence 欧盟 - 挪威文 - EMA (European Medicines Agency)

cufence

univar solutions bv - trientine dihydrochloride - hepatolentikulær degenerasjon - andre alimentary tract and metabolism products, - cufence er angitt for behandling av wilsons sykdom hos pasienter som er intolerante til d-penicillamin terapi, i voksne og barn i alderen 5 år eller eldre.

Isturisa 欧盟 - 挪威文 - EMA (European Medicines Agency)

isturisa

recordati rare diseases - osilodrostat fosfat - cushing syndrome - kortikosteroider for systemisk bruk - isturisa er angitt for behandling av endogent cushings syndrom hos voksne.

Rozlytrek 欧盟 - 挪威文 - EMA (European Medicines Agency)

rozlytrek

roche registration gmbh  - entrectinib - cancer; carcinoma, non-small-cell lung - antineoplastiske midler - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.